BAUSCH HEALTH AMERICAS, INC.
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1881
- Registration Number
- NCT01708629
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 661
- Registration Number
- NCT01708590
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 1831
- Registration Number
- NCT01708603
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01705938
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT01701024
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
- Conditions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT01647906
- Locations
- 🇺🇸
Colon and Rectal Medical Services, Los Angeles, California, United States
🇺🇸Cleveland Clinic Foundation Digestive Disease Institute, Cleveland, Ohio, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 2583
- Registration Number
- NCT01543178
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
- Conditions
- Interventions
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT01532648
- Locations
- 🇷🇺
Santarus Clinical Investigational Site 9005, Moscow, Russian Federation
🇧🇬Santarus Clinical Investigational Site 4003, Pleven, Bulgaria
🇧🇬Santarus Clinical Investigational Site 4001, Sofia, Bulgaria
AMG 827 in Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT01516957
- Locations
- 🇨🇦
Research Site, Quebec, Canada
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
- Conditions
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 951
- Registration Number
- NCT01429987
- Locations
- 🇺🇸
Southwest Gastroenterology Assoc, Oak Lawn, Illinois, United States
🇺🇸Medex Healthcare Research, Inc., Chicago, Illinois, United States
🇺🇸Advance Medical Research Service Corp, Miami, Florida, United States